The biologic agent ‘Dupixent (dupilumab)’ holds an 'unrivaled' position in the treatment of severe atopic dermatitis. In the AD treatment environment that had used immunotherapies that bring a high burden of side effects, the introduction of a safe and effective option has greatly improved the symptoms and quality of life in AD patients.

Due to its strong effect, requests for reimbursement to be extended to cover the pediatric and adolescent indications have been flooding. Unlike systemic immunosuppressants, Dupxient selectively inhibits IL-4, IL-13 signals, the key drivers of type 2 inflammation, and therefore is known as a drug that can be safely used without concern over side effects.